Journal Article

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Schrading, Simone, Umutlu, Lale, Kuhl, Christiane K., Kümmel, Sherko, Eulenburg, Christine, Harbeck, Nadia, Adams, Jascha, Prange, Anna, Nitz, Ulrike, Culemann, Ralph, Graeser, Monika, Gluz, Oleg, Strobel, Kevin, Nitzsche, Henrik, Braun, Michael, Aktas, Bahriye, Potenberg, Jochem, Forstbauer, Helmut, von Schumann, Raquel, Grischke, Eva-Maria, Frydrychowicz, Alex, Würstlein, Rachel, Kolberg-Liedtke, Cornelia, Herzog, Christopher, Rjosk-Dendorfer, Dorothea

2021

Overview

Background Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes. Methods Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values. Results A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR−/HER2+ tumors. Both methods had a comparable NPV and PPV in HR−/HER2− tumors. Conclusions In HR+/HER2+ and HR−/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT. Trial registration Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Accuracy / Adjuvant treatment / Adult / Aged / Biomedical and Life Sciences / Biomedicine / Biopsy / Breast cancer / Breast Neoplasms - diagnostic imaging / Breast Neoplasms - drug therapy / Breast Neoplasms - metabolism / Breast Neoplasms - pathology / Cancer / Cancer Research / Carboplatin / Epidermal growth factor / ErbB-2 protein / Estrogens / Female / Gynecology / Health aspects / Humans / Magnetic Resonance Imaging / Medical prognosis / Middle Aged / Neoadjuvant Therapy / Neoplasm, Residual / Oncology / Participation / Patients / Pay-per-view television / Pertuzumab / Predictions / Predictive Value of Tests / Reading / Receptor, ErbB-2 - metabolism / Receptors, Estrogen - metabolism / Receptors, Progesterone - metabolism / Research Article / Residual tumor size / Surgery / Surgical Oncology / Tumor Burden / Tumors / Ultrasonic imaging / Ultrasonography, Mammary / Ultrasound